• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Influence of a new relapse treatment for acute myeloid leukemia (AML) on in vitro granulopoiesis.

作者信息

Müller M R, Sauter C, Erni J, Martz G

出版信息

Anticancer Res. 1983 Mar-Apr;3(2):127-31.

PMID:6573868
Abstract

Twelve AML patients in relapse were treated with cytosine arabinoside (Ara-C), VP 16-213, vincristine, and vinblastine (A-triple-V). For bone marrow (BM) evaluation, in vitro granulopoiesis by agar and liquid cultures was investigated. In 15 treatments, 12 complete remissions (CR) were observed. Three patients, treated with 2 A-triple-V cycles achieved CR twice. One to four months after treatment normal colony formation and cell differentiation was found in remission patients. Evidence of sustained recovery was obtained in sequential studies of BM cultures of patients in CR. These results indicate that-A-triple-V treatment does not irreversibly deplete normal myeloid progenitor cell population.

摘要

相似文献

1
Influence of a new relapse treatment for acute myeloid leukemia (AML) on in vitro granulopoiesis.
Anticancer Res. 1983 Mar-Apr;3(2):127-31.
2
["AB-Triple V" therapy of relapsed or refractory acute myelogenous leukemia].复发或难治性急性髓系白血病的“AB-三联V”疗法
Rinsho Ketsueki. 1989 Feb;30(2):169-74.
3
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.高危白血病患者化疗清除后的外周血干细胞采集物的自体移植：一项试点研究。
Bone Marrow Transplant. 1999 Feb;23(3):235-41. doi: 10.1038/sj.bmt.1701576.
4
[Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].[70岁以上急性髓系白血病。小剂量阿糖胞苷治疗的经验]
Sangre (Barc). 1998 Feb;43(1):35-9.
5
[Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia].
Gan To Kagaku Ryoho. 1994 Feb;21(2):231-6.
6
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.复发/难治性急性髓系白血病患者接受克拉屈滨、阿糖胞苷（Ara-C）、粒细胞集落刺激因子（G-CSF）（CLAG方案）及同步递增剂量甲磺酸伊马替尼（格列卫）的I期研究。
Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026. Epub 2008 Jun 20.
7
[Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].[UHKT - 911研究针对65岁以下无良好核型的初发急性髓系白血病成年患者的长期结果]
Vnitr Lek. 2003 Mar;49(3):174-80.
8
Acute myelogenous leukemia: successful treatment of relapse with cytosine arabinoside, VP 16-213, vincristine and vinblastine (A-triple-V).急性髓性白血病：应用阿糖胞苷、依托泊苷、长春新碱和长春花碱（A-三联-V）成功治疗复发病例
Eur J Cancer Clin Oncol. 1982 Aug;18(8):733-7. doi: 10.1016/0277-5379(82)90071-2.
9
IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.IDA-FLAG方案治疗原发性难治性和复发性急性白血病：单中心经验
Am J Ther. 2006 Sep-Oct;13(5):389-93. doi: 10.1097/01.mjt.0000181690.21601.09.
10
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.FLAG-IDA方案治疗难治性/复发性急性髓系白血病：单中心经验
Ann Hematol. 2003 Apr;82(4):231-5. doi: 10.1007/s00277-003-0624-2. Epub 2003 Mar 15.

引用本文的文献

1
Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.全基因组整合分析鉴定 IDH2 R140Q 突变型急性髓系白血病潜在的分子机制和治疗靶点。
Oncol Rep. 2019 May;41(5):2876-2888. doi: 10.3892/or.2019.7075. Epub 2019 Mar 18.